KIT and neoplasm: Other investigators reported that receptor tyrosine kinase inhibitors (TKIs) such as sunitinib and dasatinib reduce signaling through the RAF/MEK/ERK pathway that is activated by ligand binding to angiogenic receptors like VEGFR-2, PDGFR-β, FH-3 and c-kit [52], indirectly inhibiting tumor growth by affecting tumor angiogenesis [52].